Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Study Following A Single Subcutaneous Injection of SHR-1209 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2018
Price : $35 *
At a glance
- Drugs SHR-1209 (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 15 Oct 2018 Status changed from not yet recruiting to recruiting.
- 23 Aug 2018 New trial record